BDBM296707 US10112942, Example 442::US10137124, Example 442::US10172851, Example 442::US10555944, Example 442::US10953005, Example 442

SMILES COc1ccc(CN2C3CC2CN(C3)c2ccc(cn2)-c2cc(OCC3CCN(C)CC3)cn3ncc(C#N)c23)cn1

InChI Key InChIKey=HOZIAULRSXYBQQ-UHFFFAOYSA-N

Data  15 IC50

  Tab Delimited (TSV)   2D SDfile   Computed 3D by Vconf -m prep SDfile
Find this compound or compounds like it in BindingDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 15 hits for monomerid = 296707   

TargetProto-oncogene tyrosine-protein kinase receptor Ret(Human)
Array Biopharma

US Patent
LigandPNGBDBM296707(US10112942, Example 442 | US10137124, Example 442 ...)
Affinity DataIC50: 13.8nMpH: 7.4Assay Description:Compounds of Formula I were screened for their ability to inhibit wildtype and V804M mutant RET kinase using CisBio's HTRF KinEASE -TK assay tech...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/4/2019
Entry Details
Go to US Patent

LigandPNGBDBM296707(US10112942, Example 442 | US10137124, Example 442 ...)
Affinity DataIC50: 21.5nMMore data for this Ligand-Target Pair
In Depth
Date in BDB:
3/4/2019
Entry Details
Go to US Patent

LigandPNGBDBM296707(US10112942, Example 442 | US10137124, Example 442 ...)
Affinity DataIC50: 101nMMore data for this Ligand-Target Pair
In Depth
Date in BDB:
3/4/2019
Entry Details
Go to US Patent

TargetProto-oncogene tyrosine-protein kinase receptor Ret(Human)
Array Biopharma

US Patent
LigandPNGBDBM296707(US10112942, Example 442 | US10137124, Example 442 ...)
Affinity DataIC50: 13.8nMAssay Description:Compounds of Formula I were screened for their ability to inhibit wildtype and V804M mutant RET kinase using CisBio's HTRF KinEASE -TK assay tech...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/29/2019
Entry Details
Go to US Patent

LigandPNGBDBM296707(US10112942, Example 442 | US10137124, Example 442 ...)
Affinity DataIC50: 21.5nMAssay Description:Compounds of Formula I were screened for their ability to inhibit wildtype and V804M mutant RET kinase using CisBio's HTRF KinEASE -TK assay tech...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/29/2019
Entry Details
Go to US Patent

LigandPNGBDBM296707(US10112942, Example 442 | US10137124, Example 442 ...)
Affinity DataIC50: 101nMAssay Description:Compounds of Formula I were screened for their ability to inhibit wildtype and V804M mutant RET kinase using CisBio's HTRF KinEASE -TK assay tech...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/29/2019
Entry Details
Go to US Patent

LigandPNGBDBM296707(US10112942, Example 442 | US10137124, Example 442 ...)
Affinity DataIC50: 13.8nMAssay Description:Compounds of Formula I were screened for their ability to inhibit wildtype and V804M mutant RET kinase using CisBio's HTRF KinEASE -TK assay tech...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/30/2019
Entry Details
Go to US Patent

LigandPNGBDBM296707(US10112942, Example 442 | US10137124, Example 442 ...)
Affinity DataIC50: 21.5nMAssay Description:Compounds of Formula I were screened for their ability to inhibit wildtype and V804M mutant RET kinase using CisBio's HTRF KinEASE -TK assay tech...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/30/2019
Entry Details
Go to US Patent

LigandPNGBDBM296707(US10112942, Example 442 | US10137124, Example 442 ...)
Affinity DataIC50: 101nMAssay Description:The potency of a compound inhibiting G81 OR mutant RET kinase was determined using CisBio's HTRF Kinease-TK assay technology. The assays containe...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/30/2019
Entry Details
Go to US Patent

LigandPNGBDBM296707(US10112942, Example 442 | US10137124, Example 442 ...)
Affinity DataIC50: 13.8nMAssay Description:Compounds of Formula I were screened for their ability to inhibit wildtype and V804M mutant RET kinase using CisBio's HTRF KinEASE-TK assay techn...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2020
Entry Details
Go to US Patent

LigandPNGBDBM296707(US10112942, Example 442 | US10137124, Example 442 ...)
Affinity DataIC50: 21.5nMAssay Description:Compounds of Formula I were screened for their ability to inhibit wildtype and V804M mutant RET kinase using CisBio's HTRF KinEASE-TK assay techn...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2020
Entry Details
Go to US Patent

LigandPNGBDBM296707(US10112942, Example 442 | US10137124, Example 442 ...)
Affinity DataIC50: 101nMAssay Description:The potency of a compound inhibiting G81 OR mutant RET kinase was determined using CisBio's HTRF Kinease-TK assay technology. The assays containe...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2020
Entry Details
Go to US Patent

TargetProto-oncogene tyrosine-protein kinase receptor Ret(Human)
Array Biopharma

US Patent
LigandPNGBDBM296707(US10112942, Example 442 | US10137124, Example 442 ...)
Affinity DataIC50: 13.8nMAssay Description:RET: Compounds of Formula I were screened for their ability to inhibit wildtype and V804M mutant RET kinase using CisBio's HTRF KinEASE -TK assay...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/28/2021
Entry Details
Go to US Patent

LigandPNGBDBM296707(US10112942, Example 442 | US10137124, Example 442 ...)
Affinity DataIC50: 21.5nMAssay Description:RET: Compounds of Formula I were screened for their ability to inhibit wildtype and V804M mutant RET kinase using CisBio's HTRF KinEASE -TK assay...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/28/2021
Entry Details
Go to US Patent

LigandPNGBDBM296707(US10112942, Example 442 | US10137124, Example 442 ...)
Affinity DataIC50: 101nMAssay Description:RET G810R: The potency of a compound inhibiting G810R mutant RET kinase was determined using CisBio's HTRF Kinease-TK assay technology. The assay...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/28/2021
Entry Details
Go to US Patent